Futura Medical (FUM)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

33.10p
   
  • Change Today:
      0.15p
  • 52 Week High: 65.00
  • 52 Week Low: 25.50
  • Currency: UK Pounds
  • Shares Issued: 301.45m
  • Volume: 180,866
  • Market Cap: £99.78m
  • RiskGrade: 479
  • Beta: 0.02

Futura's erection gel launched over-the-counter in the UK

By Josh White

Date: Tuesday 18 Apr 2023

LONDON (ShareCast) - (Sharecast News) - Sexual health-focussed pharmaceutical company Futura Medical announced on Tuesday that its topical gel formulation for the treatment of erectile dysfunction (ED), MED3000, is now available in the UK under the 'Eroxon' brand.
The AIM-traded firm said the gel would be available over the counter, and would not require a doctor's prescription, making it the first pan-European topical treatment for ED of its kind.

Its EU and UK distribution partner, Cooper Consumer Health, confirmed that Eroxon was now available for purchase from Boots online, and would be rolled out to stores from 18 April.

Futura said at least one in five men worldwide suffered from ED, with 22 million men experiencing the condition in the US, and 20 million in the UK, France, Italy, Spain, and Germany.

The problem was said to be increasing, with half of men over the age of 40 experiencing ED and a quarter of men diagnosed with ED now being under 40.

That, the company claimed, was partly due to an ageing population, increased obesity, health conditions such as diabetes, and societal pressures.

Eroxon was expected to provide benefits to those seeking a spontaneous intercourse experience, as the gel helps users to achieve an erection within 10 minutes.

Futura said many patients were dissatisfied with current treatments, adding that there had been little innovation in ED treatments in over a decade.

"We are pleased to confirm that Eroxon is available in the UK from today," said chief executive officer James Barder.

"This is a significant milestone for the company, as our distribution partners continue to increase the availability of Eroxon across different markets.

"ED is a growing problem and we believe that today's announcement will be welcomed by many men suffering from ED for whom current front-line treatments for ED are unsuitable."

At 1250 BST, shares in Futura Medical were up 9.07% at 47.33p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Futura Medical Market Data

Currency UK Pounds
Share Price 33.10p
Change Today 0.15p
% Change 0.46 %
52 Week High 65.00
52 Week Low 25.50
Volume 180,866
Shares Issued 301.45m
Market Cap £99.78m
Beta 0.02
RiskGrade 479

Futura Medical Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
46.64% below the market average46.64% below the market average46.64% below the market average46.64% below the market average46.64% below the market average
13.73% below the sector average13.73% below the sector average13.73% below the sector average13.73% below the sector average13.73% below the sector average
Price Trend
7.59% below the market average7.59% below the market average7.59% below the market average7.59% below the market average7.59% below the market average
60.71% above the sector average60.71% above the sector average60.71% above the sector average60.71% above the sector average60.71% above the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 1
Buy 1
Neutral 0
Sell 0
Strong Sell 0
Total 2
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Futura Medical Dividends

No dividends found

Trades for 01-May-2024

Time Volume / Share Price
15:33 6,952 @ 33.10p
15:28 4,253 @ 33.25p
15:28 200 @ 33.50p
15:19 119 @ 33.25p
14:59 4,482 @ 33.25p

Futura Medical Key Personnel

CEO James Henry Barder
Finance Director Angela Hildreth

Top of Page